Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

Next Previous
X
Search
Trial Profile

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Retinal oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms COPERNICUS
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 28 Nov 2022 Results of post hoc analysis of studies(COPERNICUS and GALILEO trials for CRVO and VIBRANT trial) assessing Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion published in the Graefes Archive for Clinical and Experimental Ophthalmology
    • 23 Jan 2015 According to a Regeneron Pharmaceuticals media release, aflibercept has been recommended for approval by the European CHMP for the treatment of visual impairment due to macular oedema secondary to central or branch retinal vein occlusion.
    • 12 Nov 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top